TY - JOUR T1 - SARS-CoV-2-specific T Cell Memory is Sustained in COVID-19 Convalescents for 8 Months with Successful Development of Stem Cell-like Memory T Cells JF - medRxiv DO - 10.1101/2021.03.04.21252658 SP - 2021.03.04.21252658 AU - Jae Hyung Jung AU - Min-Seok Rha AU - Moa Sa AU - Hee Kyoung Choi AU - Ji Hoon Jeon AU - Hyeri Seok AU - Dae Won Park AU - Su-Hyung Park AU - Hye Won Jeong AU - Won Suk Choi AU - Eui-Cheol Shin Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/08/2021.03.04.21252658.abstract N2 - Memory T cells contribute to rapid viral clearance during re-infection, but the longevity and differentiation of SARS-CoV-2-specific memory T cells remain unclear. We conducted direct ex vivo assays to evaluate SARS-CoV-2-specific CD4+ and CD8+ T cell responses in COVID-19 convalescents up to 254 days post-symptom onset (DPSO). Here, we report that memory T cell responses were maintained during the study period. In particular, we observed sustained polyfunctionality and proliferation capacity of SARS-CoV-2-specific T cells. Among SARS-CoV-2-specific CD4+ and CD8+ T cells detected by activation-induced markers, the proportion of stem cell-like memory T (TSCM) cells increased, peaking at approximately 120 DPSO. Development of TSCM cells was confirmed by SARS-CoV-2-specific MHC-I multimer staining. Considering the self-renewal capacity and multipotency of TSCM cells, our data suggest that SARS-CoV-2-specific T cells are long-lasting after recovery from COVID-19. The current study provides insight for establishing an effective vaccination program and epidemiological measurement.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Samsung Science and Technology Foundation under Project Number SSTF-BA1402-51, and the Mobile Clinic Module Project funded by KAIST.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This ethics of this study was reviewed and approved by Institutional Review Boards of Korea University College of Medicine, Ansan Hospital and Chungbuk National University College of Medicine. This study was conducted according to the principles of the Declaration of Helsinki.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon request. ER -